Granules India gets zero observations from USFDA for Unit V facility in Andhra Pradesh

13 Apr 2024 Evaluate

Granules India’s Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India underwent a United States Food and Drug Administration (USFDA) inspection from April 8, 2024 to April 12, 2024. This audit was a Pre Approval Inspection (PAI) and cGMP audit for Active Pharmaceutical Ingredients (APIs) and Formulations (FDs); oncology and non-oncology. The audit resulted in Form-483 with zero observations. This facility manufactures APIs & formulations of oncology and non-oncology products.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.